Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 1/20 | 0.58 |
| ▸ | RXRB | P28702 | 1/20 | 0.58 |
| ▸ | RXRG | P48443 | 1/20 | 0.58 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.42 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.42 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.42 |
| ▸ | MGLL | Q99685 | 1/20 | 0.41 |
| ▸ | CYP4F2 | P78329 | 3/20 | 0.40 |
| ▸ | CYP4A11 | Q02928 | 3/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.40 |
| ▸ | SYK | P43405 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | FDFT1 | P37268 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14815898 | 0.83 | RXRA (0.61) | RXRARXRBRXRGCYP4F2CYP4A11 | |
| SCHEMBL14553593 | 0.82 | RXRA (0.65) | RXRARXRBRXRGCYP4F2CYP4A11 | |
| SCHEMBL10231494 | 0.82 | RXRA (0.64) | RXRARXRBRXRGCYP4F2CYP4A11 | |
| SCHEMBL16596005 | 0.80 | RXRA (0.55) | RXRARXRBRXRGP2RY12CYP4F2 | |
| SCHEMBL14553594 | 0.80 | RXRA (0.62) | RXRARXRBRXRGCYP4F2CYP4A11 | |
| SCHEMBL10231475 | 0.80 | RXRA (0.62) | RXRARXRBRXRGCYP4F2CYP4A11 | |
| SCHEMBL29433054 | 0.80 | RXRA (0.67) | RXRARXRBRXRGCYP4F2CYP4A11 | |
| SCHEMBL10231496 | 0.80 | RXRA (0.67) | RXRARXRBRXRGCYP4F2CYP4A11 | |
| SCHEMBL14827612 | 0.80 | RXRA (0.52) | RXRARXRBRXRGP2RY12MGLL | |
| SCHEMBL785313 | 0.79 | RXRA (0.61) | RXRARXRBRXRGCYP4F2CYP4A11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2760856-B1 | SELECTIVE NR2B ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2016-09-14 | — | — | EP | disclosed |
| EP-2760856-B1 | SELECTIVE NR2B ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2016-09-14 | — | — | EP | disclosed |
| EP-2760856-A1 | SELECTIVE NR2B ANTAGONISTS | Bristol-Myers Squibb Company (US) | 2014-08-06 | — | — | EP | disclosed |
| US-8722670-B2 | Selective NR2B antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-05-13 | — | — | US | disclosed |
| US-8722670-B2 | Selective NR2B antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-05-13 | — | — | US | disclosed |
| US-8722670-B2 | Selective NR2B antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-05-13 | — | — | US | disclosed |
| WO-2013049119-A1 | SELECTIVE NR2B ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-04-04 | — | — | WO | disclosed |
| WO-2013049119-A1 | SELECTIVE NR2B ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-04-04 | — | — | WO | disclosed |
| US-20130085138-A1 | Selective NR2B Antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-04-04 | — | — | US | disclosed |
| US-20130085138-A1 | Selective NR2B Antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-04-04 | — | — | US | disclosed |
| US-20130085138-A1 | Selective NR2B Antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-04-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130085138-A1 | Selective NR2B Antagonists | GRIN2B, GRIN2A, GRIN3A | RXRA 1503/4885RXRB 1119/4885RXRG 1000/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.